<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885572</url>
  </required_header>
  <id_info>
    <org_study_id>pfm 12k001 TiLOOP Bra</org_study_id>
    <nct_id>NCT01885572</nct_id>
  </id_info>
  <brief_title>National, Multicenter PMS Study &quot;Patient Reported Outcome&quot; in Breast Reconstruction Following Mastectomy With TiLOOP Bra</brief_title>
  <acronym>PRO-BRA</acronym>
  <official_title>National, Multicenter Post-market Surveillance Study &quot;Patient Reported Outcome&quot; in Breast Reconstruction Following Mastectomy With Titaniferously Coated Polypropylene Mesh (TiLOOP Bra)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfm Medical Mepro Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>pfm medical ag</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfm Medical Mepro Gmbh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre, non-randomised, observational clinical device investigation will be&#xD;
      performed to obtain postmarketing information on the TiLOOP® Bra and in particular on the&#xD;
      improvement of the patients' quality of life as well as on the rate of complications of the&#xD;
      device under investigation.&#xD;
&#xD;
      The objective of this clinical investigation is to establish the feasibility, efficacy and&#xD;
      safety of the TiLOOP® Bra.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRO</measure>
    <time_frame>12 months after breast reconstruction</time_frame>
    <description>Measurement of the Patient Reported Outcome (PRO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRO</measure>
    <time_frame>6 and 24 months after breast reconstruction</time_frame>
    <description>Measurement of the Patient Reported Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication Rate</measure>
    <time_frame>after 6, 12 and 24 months</time_frame>
    <description>Complication rate of the first 60 patients in the 6 month follow-up and of all patients after 6, 12 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Success</measure>
    <time_frame>6, 12 and 24 months after breast reconstruction</time_frame>
    <description>Cosmetic success confirming the reinforcement will be assessed by the patient and an independent professional at a photo. The questions posed are part of the validated Breast Q questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO and Complication Rate</measure>
    <time_frame>48 months after breast reconstruction</time_frame>
    <description>Measurement of the Patient Reported Outcome and complication rate of all patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Breast Reconstruction After Mastectomy</condition>
  <arm_group>
    <arm_group_label>TiLOOP Bra</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with TiLOOP Bra</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TiLOOP Bra</intervention_name>
    <description>Titaniferously coated polypropylene mesh</description>
    <arm_group_label>TiLOOP Bra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The TiLOOP®Bra is designed to assist oncologically indexed skin sparing mastectomy or&#xD;
        subcutaneous mastectomy with preservation of the nipple-areola-complex during primary&#xD;
        breast reconstruction, secondary breast reconstruction or corrective breast surgery.&#xD;
        Patients shall be included if they meet all of the following criteria:&#xD;
&#xD;
        Clinical Criteria (reason):&#xD;
&#xD;
          -  women with indication of prophylactic operation or oncoplastic operation with support&#xD;
             of a mesh implant&#xD;
&#xD;
          -  women with histologically confirmed breast cancer or precancerosis or genetic&#xD;
             pre-existing conditions with increased risk of breast cancer or with a family history&#xD;
&#xD;
          -  the health of women must comply with ECOG (Eastern Cooperative Oncology Group)&#xD;
             performance status 0-2&#xD;
&#xD;
        Study-related inclusion criteria - Legal reasons:&#xD;
&#xD;
          -  Patient is mentally able to understand the nature, aims, or possible consequences of&#xD;
             the clinical investigation&#xD;
&#xD;
          -  Patient information has been handed out and all written consents are at hand.&#xD;
&#xD;
          -  Patient is between 18 and 70 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients must be excluded if any of the following conditions exist or cannot be excluded:&#xD;
&#xD;
        Device-related exclusion criteria (contraindications):&#xD;
&#xD;
        Pathological or physical condition precluding such as:&#xD;
&#xD;
          -  Pregnancy or breast-feeding patients&#xD;
&#xD;
          -  Known intolerance to the mesh-implants under investigation.&#xD;
&#xD;
        Study-related exclusion criteria - Medical reasons:&#xD;
&#xD;
          -  metastatic breast cancer&#xD;
&#xD;
          -  medicamentous regulated diabetes with blood sugar level &gt;250&#xD;
&#xD;
          -  inadequate bone marrow function with neutrophil granulocytes &lt;1500 and blood plates &lt;&#xD;
             10000/µl&#xD;
&#xD;
          -  patient with known contraindication to mesh-implants or plastic-reconstructive breast&#xD;
             operations&#xD;
&#xD;
        Study-related exclusion criteria - Legal reasons:&#xD;
&#xD;
          -  Lack of written patients informed consent.&#xD;
&#xD;
          -  Lack of patient compliance regarding data collection, treatment or follow-up&#xD;
             investigations in the scope of the protocol.&#xD;
&#xD;
          -  Patient is institutionalized by court or official order (MPG§20.3).&#xD;
&#xD;
          -  Participation in another operative clinical investigation.&#xD;
&#xD;
        It is thought that the study-related exclusion criteria will not significantly influence&#xD;
        the sample of the population under investigation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Paepke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University Munich, Ismaningerstrasse 22, 81675 Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Campus Mitte and Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Gertrauden Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Kliniken am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Krankenhaus</name>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Thill M, Faridi A, Meiré A, Gerber-Schäfer C, Baumann K, Blohmer JU, Mau C, Tofall S, Nolte E, Strittmatter HJ, Ohlinger R, Paepke S. Patient reported outcome and cosmetic evaluation following implant-based breast-reconstruction with a titanized polypropylene mesh (TiLOOP® Bra): A prospective clinical study in 269 patients. Eur J Surg Oncol. 2020 Aug;46(8):1484-1490. doi: 10.1016/j.ejso.2020.04.009. Epub 2020 Apr 15.</citation>
    <PMID>32336622</PMID>
  </results_reference>
  <results_reference>
    <citation>Nolte E, Klein E, Paepke S. Pregnancy following Unilateral Immediate Breast Reconstruction with Titanized Polypropylene Mesh (TiLOOP(R) Bra) without Compromising the Result. Plast Reconstr Surg Glob Open. 2018 Sep 14;6(9):e1919. doi: 10.1097/GOX.0000000000001919. eCollection 2018 Sep.</citation>
    <PMID>30349788</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast reconstruction</keyword>
  <keyword>mastectomy</keyword>
  <keyword>mesh</keyword>
  <keyword>breast cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

